Based on evidence in animals (423) and humans (424), a key pathogenic role of IGF-1 in ALS was suggested (425), leading to the therapeutic use of this growth factor, first in animal models (425, 426), and then in clinical trials (427, 428). This evidence concerns the gene IGF1 and amyotrophic lateral sclerosis.